Jul 14, 2025 8:00 am EDT Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
May 16, 2025 8:50 pm EDT Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
May 15, 2025 8:35 am EDT Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
May 05, 2025 5:06 pm EDT Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
Mar 07, 2025 4:01 pm EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
Feb 07, 2025 4:01 pm EST Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 21, 2025 7:30 am EST Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
Jan 16, 2025 8:30 am EST Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
Nov 27, 2024 4:01 pm EST Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference